Overview

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
BI 425809